Weekly Recap: $36.50 tender offer and majority, antitrust conditions

What happened

Viatris offered $36.50 per share in cash for all Pacira Biosciences shares. Pacira’s board unanimously recommended the tender offer, which expires November 16, 2026. The offer requires tenders from more than 50% of shares, antitrust clearance and no legal blocks, and has no financing condition.

Confirmed

Global impact / market context

If enough shareholders tender and the required clearances and legal conditions are met, Viatris could acquire Pacira. That would convert shareholders’ holdings into cash and transfer ownership of the business; failure to satisfy a condition could prevent the transaction and leave Pacira operating independently.

Analyst inference

The offer sets a stated cash amount per share, but the article gives no current share price or expected completion date beyond the offer’s expiration. Because completion depends on shareholder tenders and regulatory and legal conditions, the cash amount is not a guaranteed outcome for shareholders.

Analyst inference

What to watch

1. Whether shareholders tender more than 50% of Pacira’s shares before the offer expires on November 16, 2026; the board recommends accepting, but shareholders decide individually. Confirmed
2. Whether antitrust clearance is granted and whether any legal blocks arise; antitrust clearance means regulatory approval for the takeover, and both are stated conditions that could stop it. Confirmed
3. Any change to the offer terms or expiration date could alter shareholders’ decision window; the article reports no financing condition, so funding is not listed as a hurdle. Analyst inference

Evidence

• Original source link unavailable